Safe Conversion From Tacrolimus to Belatacept in High Immunologic Risk Kidney Transplant Recipients With Allograft Dysfunction

Publisher： John Wiley & Sons Inc

E-ISSN： 1600-6143|15|10|2726-2731

ISSN： 1600-6135

Source： AMERICAN JOURNAL OF TRANSPLANTATION, Vol.15, Iss.10, 2015-10, pp. : 2726-2731

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Safe Conversion From Tacrolimus to Belatacept in High Immunologic Risk Kidney Transplant Recipients With Allograft Dysfunction

By  

AMERICAN JOURNAL OF TRANSPLANTATION, Vol. 1600-6135, Iss. 10, 2015-10 ,pp. : 2726-2731

John Wiley & Sons Inc

Access to resources Recommend Favorite

Belatacept for kidney transplant recipients

By  

NEPHROLOGY, Vol. 20, Iss. 10, 2015-10 ,pp. : 752-754

John Wiley & Sons Inc

Access to resources Recommend Favorite

Does belatacept improve outcomes for kidney transplant recipients? A systematic review

By  

TRANSPLANT INTERNATIONAL (ELECTRONIC), Vol. 934-0874, Iss. 11, 2015-11 ,pp. : 1251-1264

John Wiley & Sons Inc

Access to resources Recommend Favorite

Does belatacept improve outcomes for kidney transplant recipients? A systematic review

By  

TRANSPLANT INTERNATIONAL (ELECTRONIC), Vol. 28, Iss. 11, 2015-11 ,pp. : 1251-1264

John Wiley & Sons Inc

Access to resources Recommend Favorite

Conversion from twice‐daily to once‐daily tacrolimus formulation in pediatric liver transplant recipients – a long‐term prospective study

By  

TRANSPLANT INTERNATIONAL (ELECTRONIC), Vol. 31, Iss. 1, 2018-01 ,pp. : 38-44

John Wiley & Sons Inc

Access to resources Recommend Favorite